FGP
HAE icon

Freestone Grove Partners’s Haemonetics HAE Stock Holding History

Freestone Grove Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Sell
4,737
-4,235
-47% -$272K ﹤0.01% 720
2026
Q1 		$506K Buy
+8,972
New +$584K ﹤0.01% 595
2025
Q4 		– Sell
-30,260
Closed -$1.47M – 810
2025
Q3 		$1.47M Buy
+30,260
New +$1.87M 0.01% 398

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's HAE Position: Q2 2026 in Review

Freestone Grove Partners reduced its Haemonetics (HAE) stake by 47% in Q2 2026, selling an estimated $272K and leaving 4,737 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Freestone Grove Partners first reported a position in HAE in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.47M in Q3 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Freestone Grove Partners held 4,737 shares of Haemonetics worth $355K as of Q2 2026.
  • Freestone Grove Partners sold 4,235 Haemonetics shares in Q2 2026, an estimated $272K.
  • Haemonetics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #720 holding.
  • Freestone Grove Partners first reported a position in Haemonetics in Q3 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Haemonetics position peaked at $1.47M in Q3 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.